Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05633654 |
|---|---|
| Brief Title: | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63) |
| First Submitted : | November 21, 2022 |
| First Submitted that Met QC Criteria : | November 21, 2022 |
| First Posted : | December 1, 2022 |
| Last Update Submitted that Met QC Criteria : | April 30, 2024 |
| Last Update Posted : | May 1, 2024 |